Table 1.
Before Treatment |
Treatment | After 3 Mass Treatments |
|||||||||
% (No./Total) |
Mean (SD) | % (No./Total) |
|||||||||
Community | TF/TIa | DNAb | % Coveragec | TF/TIa | DNAb | RNAd | |||||
1 | 89.6 | (43/48) | 44.9 | (22/49) | 83.4 (9.2) | 46.9 | (23/49) | 18.4 | (9/49) | 28.6 | (14/49) |
2 | 64.0 | (32/50) | 46.0 | (23/50) | 73.5 (12.3) | 65.3 | (32/49) | 8.2 | (4/49) | 10.2 | (5/49) |
3 | 59.2 | (29/49) | 53.1 | (26/49) | 90.4 (5.2) | 50.9 | (27/53) | 0.0 | (0/53) | 0.0 | (0/53) |
4 | 72.0 | (36/50) | 52.0 | (26/50) | 97.8 (2.3) | 41.7 | (20/48) | 0.0 | (0/48) | 0.0 | (0/48) |
5 | 84.0 | (42/50) | 56.0 | (28/50) | 92.0 (5.3) | 29.4 | (15/50) | 2.0 | (1/50) | 4.0 | (2/50) |
6 | 40.8 | (20/49) | 14.0 | (7/50) | 91.7 (6.6) | 38.0 | (19/50) | 2.0 | (1/49) | 2.0 | (1/49) |
7 | 94.4 | (34/36) | 16.7 | (6/36) | 85.6 (3.0) | 48.5 | (16/33) | 0.0 | (0/33) | 3.0 | (1/33) |
8 | 42.0 | (21/50) | 36.0 | (18/50) | 94.8 (3.7) | 45.8 | (22/48) | 2.1 | (1/48) | 4.2 | (2/48) |
9 | 92.0 | (46/50) | 58.0 | (29/50) | 86.1 (5.0) | 63.5 | (33/52) | 13.5 | (7/52) | 26.9 | (14/52) |
10 | 62.5 | (30/48) | 22.4 | (11/49) | 78.4 (30.0) | 18.0 | (9/50) | 0.0 | (0/51) | 0.0 | (0/51) |
11 | 80.0 | (40/50) | 62.0 | (31/50) | 85.6 (4.4) | 32.6 | (14/43) | 0.0 | (0/45) | 0.0 | (0/45) |
12 | 44.4 | (20/45) | 41.2 | (21/51) | 82.1 (11.5) | 40.7 | (22/54) | 3.7 | (2/54) | 3.7 | (2/54) |
Mean (95% CI) | 68.7 | (56.3–81.2) | 41.9 | (31.5–52.2) | 86.8 (82.4–91.2) | 43.5 | (35.0–52.0) | 4.2 | (0.3–8.0) | 6.9 | (0.4–13.3) |
Abbreviations: CI, confidence interval; TF, follicular trachomatous inflammation; TI, intense trachomatous inflammation.
TF and/or TI, according to the World Health Organization simplified grading system [9].
DNA evidence of ocular chlamydia, tested with AMPLICOR-CT.
Mean antibiotic coverage during mass azithromycin distributions at months 0, 12, and 24.
RNA evidence of ocular chlamydia, tested with APTIMA-CT.